Announcements
May 22-25, 2010Hemmerling A, Harrison W, Schroeder A, Parks J, Korn A, Foster-Rosales...
May 22-25, 2010Ngugi B, Hemmerling A, Bukusi E, Kikuvi G, Gikunju J, Shiboski S, Fredericks...
October 2009Stapleton AE, Au-Yeung M, Yarova-Yarovaya Y, Fredricks DN, Czaja C, Scholes...
About Osel
Osel Inc. is a biopharmaceutical company with a proprietary technology platform to develop next-generation probiotics as pharmaceutical products to address major gastrointestinal (“GI”), infectious diseases and women’s health indications. Probiotics are widely used in Europe and Asia, and are rapidly gaining acceptance in the US. The global probiotics market is estimated to reach US $31.2 billion in 2014 with a CAGR of 11.7% from 2009 to 2014.
Osel's Mission
Osel’s Mission Statement Develop next-generation probiotics as pharmaceutical products based on rigorous science, high quality manufacturing and FDA-sanctioned clinical development.